According to the China Pharmaceutical Public Account, the first batch of Pfizer’s new crown oral drug was shipped to the front line of anti-epidemic. This drug is called naimatevir tablet/ritonavir tablet combination package (Paxlovid), which was approved in China not long ago and is represented by China Pharmaceutical in China. Sale. According to the information obtained in the meeting of the New Crown Drug Exchange Minutes of Chinese medical experts, the combination of nematicavir tablets and ritonavir tablets contains 30 tablets in a box, which can be taken for 5 days, and one box corresponds to one course of treatment for one person.
In terms of price, the result of price negotiation between Pfizer, the National Health Commission and China Medicine is not market behavior. The price of a box is a little more than 1,000 yuan, and medical insurance pays.
This medicine will be like a vaccine. If the patient needs it, it will be given to the patient for free, and the medical insurance will pay.
It is reported that Paxlovid is an oral small molecule new coronavirus treatment drug, a combination of nematevir and ritonavir.
Paxlovid can be used to treat adult patients with mild to moderate novel coronavirus pneumonia (COVID-19) with high risk factors for progression to severe disease, such as advanced age, chronic kidney disease, diabetes, cardiovascular disease, chronic lung disease and other high risk of severe disease factor patients.
In terms of effectiveness, according to data released by Pfizer at the end of 2021, compared with placebo, Paxlovid, taken within three days of onset of symptoms, can reduce the probability of hospitalization or death in mild and moderate adult patients by 89%.
